Blood Glucose Monitoring Devices Market Size & Share, by Product (Self-Monitoring Devices, Continuous Glucose Monitoring Devices); Modality (Wearable, Non-Wearable); Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); Distribution Channel (Hospitals, Retail Sales, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4606
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Companies Dominating the Blood Glucose Monitoring Devices Landscape

    • Abbott Laboratories
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • Ascensia Diabetes Care Holdings AG
    • Dexcom, Inc.
    • Prodigy Diabetes Care, LLC
    • ACON Laboratories, Inc.
    • Insulet Corporation
    • Ypsomed AG
    • Terumo Corporation

Browse Key Market Insights with Data Illustration:


In The News

  • Abbott Laboratories announced new data from the Real-World Evidence of FreeStyle Libre study showing the use of freestyle libre, a continuous glucose monitoring system significantly reduced the rate of hospitalizations.

  • F. Hoffmann-La Roche Ltd launched the cobas pulse system, a connected professional blood glucose management solution that builds on its inheritance with Accu-Chek Inform II. Healthcare professionals working in a variety of care settings can use this handheld blood glucose management device to monitor the blood glucose levels of patients.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4606
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing perforation of continuous blood glucose monitoring (CGM) devices, rising ubiquity of diabetes, and growing investment in diabetic research activities are the major factors driving the market growth.

The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2023 - 2033.

Lower diagnosis & treatment rate of diabetes, and inadequate approach to advanced healthcare infrastructure are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Ascensia Diabetes Care Holdings AG, Dexcom, Inc., NIPRO CORPORATION, ACON Laboratories, Inc., Insulet Corporation, Ypsomed AG, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, modality, disease type, distribution channel, and by region.

The self-monitoring devices segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying